During 2018 Q3 the big money sentiment increased to 1.15. That’s change of 0.14, from 2018Q2’s 1.01. 42 investors sold all, 88 reduced holdings as Exact Sciences Corporation ratio improved. 87 rose stakes while 62 funds took stakes. Funds hold 106.63 million shares thus 6.22% more from 2018Q2’s 100.39 million shares.
Moreover, Friess Associates Lc has 0.51% invested in Exact Sciences Corporation (NASDAQ:EXAS). Thompson Mngmt owns 2.67% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 189,404 shs. Moreover, Sectoral Asset Management has 2.19% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 261,050 shs. Horseman Capital Mngmt reported 0.5% of its capital in Exact Sciences Corporation (NASDAQ:EXAS). Piedmont Inv Advsr invested 0.03% of its capital in Exact Sciences Corporation (NASDAQ:EXAS). Lpl Lc has invested 0.01% of its capital in Exact Sciences Corporation (NASDAQ:EXAS). Gilder Gagnon Howe And Limited Company reported 1.95M shs or 1.57% of all its holdings. Moreover, Blackrock has 0.02% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 5.11 million shs. Newtyn Mngmt Ltd Liability Corporation owns 150,000 shs. Fulton Natl Bank Na invested in 2,631 shs or 0.01% of the stock. Employees Retirement Association Of Colorado reported 0.01% in Exact Sciences Corporation (NASDAQ:EXAS). Natixis Advsrs L P invested in 0.01% or 11,581 shs. Sterling Cap Ltd Liability Co invested in 0.04% or 50,649 shs. Private Wealth Prns Ltd Liability has invested 0.84% of its capital in Exact Sciences Corporation (NASDAQ:EXAS). Bessemer Gp stated it has 0% in Exact Sciences Corporation (NASDAQ:EXAS).

Exact Sciences Corporation had 8 selling transactions and 0 insider buys since September 30, 2018. This’s net activity of $58.02 million. $174,118 worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by COWARD D SCOTT. On Thursday, January 24 Shares for $24.74M were sold by Conroy Kevin T. 90,909 shs were sold by Elliott Jeffrey Thomas, worth $7.17M on Wednesday, January 23.

Exact Sciences Corporation (NASDAQ:EXAS) decreased to $91.04. On Feb, 28 the move was announced by Barchart.com. Exact Sciences Corporation (NASDAQ:EXAS) has $11.45 billion market cap. At $87.40 stock price target, the company valuation changes by $458.00M less.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

In total 7 analysts cover Exact Sciences (NASDAQ:EXAS). “Buy” rating has 7, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 12 are the (NASDAQ:EXAS)’s analyst reports since September 6, 2018 according to StockzIntelligence Inc. On Friday, February 22 the rating was maintained by Canaccord Genuity with “Buy”. In Wednesday, September 12 report Canaccord Genuity maintained the stock with “Buy” rating. On Friday, February 22 the company was maintained by BTIG Research. On Wednesday, October 31 the rating was maintained by Jefferies with “Buy”. On Thursday, November 29 the company was maintained by UBS. On Thursday, September 6 the rating was maintained by Bank of America with “Buy”. On Tuesday, September 11 the stock has “Outperform” rating by Robert W. Baird. In Friday, February 22 report UBS maintained it with “Buy” rating and $109 target. On Friday, February 22 the company was maintained by Craig Hallum. On Thursday, February 21 Robert W. Baird maintained the shares of EXAS in report with “Buy” rating.

For more Exact Sciences Corporation (NASDAQ:EXAS) news announced recently go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Exact Sciences (EXAS) in Focus: Stock Moves 11.6% Higher – Nasdaq” announced on April 30, 2018, “Could Exact Sciences Be a Millionaire-Maker Stock? – Nasdaq” on February 17, 2019, “EXACT Sciences Breaks Below 200-Day Moving Average – Notable for EXAS – Nasdaq” with a publish date: December 20, 2018, “Analysts Estimate Exact Sciences (EXAS) to Report a Decline in Earnings: What to Look Out for – Nasdaq” and the last “Health Care Sector Update for 01/14/2019: RWLK,EXAS,MBOT,VRNA – Nasdaq” with publication date: January 14, 2019.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States.The firm is valued at $11.45 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer.Last it reported negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.